To The Moon

$Surf Air Mobility Inc.(SRFM)$   Extremely frustrating stock to hold. SRFM has become the kind of stock where shareholders seem to spend more time worrying about the next drop than enjoying any meaningful upside. Even when there is seemingly positive news or better revenue, the share price struggles to hold its gains and repeatedly gets sold down. Today is another example — it opened around $0.795, plunged to about $0.752, and is still struggling below $0.80. Every small recovery seems to meet another wall of sellers. What concerns me most is that this is already a sub-$1 stock with NYSE compliance issues and reverse-stock-split risk hanging over shareholders. That creates an uncomfortable situation where investors aren't just evaluating the

$Stagwell Inc.(STGW)$   Stagwell is an interesting alternative to the much larger traditional advertising groups, with a strategy increasingly focused on digital marketing, technology and data-driven services. As companies continue shifting advertising budgets toward digital channels and increasingly incorporate AI into marketing workflows, agencies capable of combining creative expertise with technology could benefit. STGW doesn't receive the attention given to fashionable AI or semiconductor stocks, which may actually be part of the opportunity if earnings and cash generation improve. Overall: STGW is a less obvious growth story, but its digital focus, technology exposure and potential for improving profitability make it an interesting smal

$IONQ Inc.(IONQ)$   IonQ offers something relatively rare in public markets: direct exposure to the emerging quantum-computing industry. If quantum computers eventually solve commercially important problems that conventional computers struggle with, the addressable opportunity could become enormous across areas such as pharmaceuticals, materials science, optimisation and cybersecurity. But this is still an emerging technology. Investors are valuing IonQ largely on what the company could become rather than today's earnings, making the stock particularly sensitive to expectations. Overall: IONQ is unquestionably speculative, but that's part of its appeal. If quantum computing develops into a major computing platform and IonQ establishes it

$JPMorgan Chase(JPM)$   JPMorgan Chase has repeatedly demonstrated why it is regarded as one of America's strongest banks. Its enormous scale spans consumer banking, credit cards, commercial banking, investment banking, trading and asset management. This diversification means weakness in one part of the financial system can sometimes be offset by strength elsewhere. Its strong balance sheet and ability to gain market share during periods of financial stress further distinguish JPMorgan from weaker competitors. Overall: JPM combines scale, diversification and excellent execution. For investors wanting long-term exposure to the US financial system, JPMorgan remains arguably the benchmark banking franchise.

$Berkshire Hathaway(BRK.B)$   Berkshire Hathaway is essentially an enormous collection of high-quality businesses assembled under one exceptionally strong balance sheet. Its operations span insurance, railroads, energy, manufacturing and consumer businesses, supplemented by a huge investment portfolio. The insurance operation is particularly valuable because its float provides Berkshire with capital that can be invested elsewhere, while its enormous liquidity gives the company the ability to deploy capital aggressively when opportunities emerge. The post-Buffett era naturally introduces questions about capital allocation, but Berkshire's underlying businesses and financial strength remain formidable. Overall: BRK.B isn't designed to pro

$Exxon Mobil(XOM)$   Exxon Mobil remains a heavyweight of the global energy industry, with enormous upstream, refining and chemical operations providing diversification that smaller producers cannot replicate. Its scale, high-quality assets and disciplined capital allocation give Exxon considerable cash-generating power when commodity conditions are favourable. At the same time, investments in areas such as carbon capture and lower-carbon technologies provide optionality as the energy landscape evolves. Overall: XOM is not a speculative oil bet. It is a highly diversified energy giant with enormous assets, strong cash-flow potential and the financial strength to survive commodity cycles.

$MINISO Group Holding Limited(MNSO)$   MINISO has built a remarkably recognisable retail concept around affordable lifestyle products, collectibles and collaborations with popular intellectual properties. Its international expansion is particularly interesting. The company has demonstrated that its retail concept can travel beyond China, giving MINISO a much larger potential market than investors might initially assume. The combination of affordable products, rapidly changing merchandise and popular character collaborations can generate repeat customer traffic. Overall: MNSO is an interesting combination of Chinese consumer growth and international retail expansion. If the brand continues gaining traction globally, there remains meaningf

$NIO Inc.(NIO)$   NIO remains one of China's best-known premium EV manufacturers, and its technology, vehicle design and battery-swapping ecosystem differentiate it from many competitors. At around $4.50, however, expectations are dramatically different from the enthusiasm surrounding NIO several years ago. That creates an interesting contrarian setup: investors no longer need perfection for the stock to recover substantially. The challenge is profitability. China's EV market is brutally competitive, and NIO needs to demonstrate that increasing deliveries can eventually translate into sustainable margins and cash generation. Overall: NIO remains high risk, but the depressed share price combined with its established brand and EV technology

$Eli Lilly(LLY)$   Eli Lilly has become one of the most impressive pharmaceutical companies in the world, supported by major franchises across diabetes, obesity and other serious diseases. The enormous demand for GLP-1 treatments has transformed Lilly's growth outlook, while its broader research pipeline provides opportunities extending well beyond today's blockbuster products. The obesity market alone could remain one of the pharmaceutical industry's largest opportunities for many years. The biggest concern is valuation. At around $1,200, investors are already pricing in considerable future success, so even a great company can experience meaningful corrections. Overall: LLY combines blockbuster medicines, powerful structural growth and a

$GRAIL, Inc.(GRAL)$   GRAIL is pursuing one of the most ambitious goals in healthcare: detecting multiple types of cancer from a blood sample, potentially before symptoms appear. The potential significance is enormous. Cancer outcomes are often dramatically better when the disease is identified earlier, meaning successful widespread adoption of multi-cancer early detection could eventually change how cancer screening is performed. That enormous opportunity comes with equally important risks. Clinical evidence, reimbursement, regulatory developments and commercial adoption will ultimately determine whether the technology fulfils its promise. Overall: GRAL is a speculative healthcare investment, but the underlying opportunity is extraordinary.